List of Excipients in Branded Drug ANZEMET

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Validus Pharmaceuticals LLC	ANZEMET	dolasetron mesylate	30698-120	CARNAUBA WAX
Validus Pharmaceuticals LLC	ANZEMET	dolasetron mesylate	30698-120	CROSCARMELLOSE SODIUM
Validus Pharmaceuticals LLC	ANZEMET	dolasetron mesylate	30698-120	FERRIC OXIDE RED
Validus Pharmaceuticals LLC	ANZEMET	dolasetron mesylate	30698-120	FERROSOFERRIC OXIDE
Validus Pharmaceuticals LLC	ANZEMET	dolasetron mesylate	30698-120	HYPROMELLOSES
Validus Pharmaceuticals LLC	ANZEMET	dolasetron mesylate	30698-120	LACTOSE
Validus Pharmaceuticals LLC	ANZEMET	dolasetron mesylate	30698-120	MAGNESIUM STEARATE

Last updated: July 28, 2026

ANZEMET (dolasetron) excipient strategy and commercial opportunities: formulation, patent landscape, and generic risk

Executive summary: ANZEMET is dolasetron (as dolasetron mesylate) indicated for chemotherapy-induced nausea and vomiting (CINV). ANZEMET is sold in the US in an oral tablet and an injectable dosage form (depending on market availability). Commercial upside for an excipient-led strategy clusters around (1) improving solubility, permeability, and stability for dolasetron’s physicochemical constraints; (2) reducing administration burden and breakthrough dosing variability in the injectable; (3) positioning for line extensions where combination with contemporary CINV regimens can be packaged with differentiated dosage forms. IP leverage typically sits less in excipients themselves and more in formulation composition, solid state (polymorph/hydrate/particle engineering), manufacturing process controls, and stability/compatibility claims that cover specific excipient systems.

Hard data requirement note: This analysis is constrained to excipient strategy and commercial opportunities. A complete, jurisdiction-level patent claim map and Orange Book–style listing of all listed patents require the drug’s current FDA catalog entries and exact NDA/ANDA numbers. Without those identifiers, patent-by-patent coverage would be incomplete.

---

What patents protect ANZEMET (dolasetron) formulations and excipient systems?

Featured snippet answer: Formulation and process patents that protect ANZEMET-style dosages generally cover the exact excipient composition, concentration ranges, and manufacturing process steps needed to achieve specified stability, dissolution, and bioavailability targets. The strongest enforceable patents typically claim a specific formulation rather than an excipient class in the abstract.

Which formulation patent types tend to bind excipient strategy

Excipient strategy is most often constrained by patents in these buckets:

• Composition-of-matter for dosage forms (formulation claims): exact ratios of dolasetron with one or more excipients (binders, disintegrants, lubricants, surfactants, solubilizers, tonicity agents, buffers).
• Solid-state form claims: polymorphs, hydrates, solvates, and engineered particle size distributions where excipients support stabilization.
• Process claims tied to excipient behavior: granulation drying endpoints, milling parameters, spray coating processes, or lyophilization/solidification conditions for the injectable.
• Stability and compatibility claims: specific pH windows, antioxidants, chelators, and packaging interactions (e.g., glass/stopper compatibility).
• Method-of-use claims are secondary for excipient entrants: excipients rarely drive a standalone method-of-use patent, but formulation patents can support labeling changes (where allowed).

Where excipient work creates patentable differentiation

For dolasetron-based products, excipient-enabled differentiation usually targets:

• Improved solubility and dissolution rate for oral products (disintegrant choice, surfactant level, particle size).
• Reduced degradation for injectables through pH control and protective excipients (buffer system selection, antioxidant/chelators, water activity control).
• Reduced precipitation risk upon dilution or co-administration in infusion workflows (solubilizers, tonicity agents, viscosity modifiers).
• Better manageability for pharmacy workflows (reconstitution time, mix volume, osmolality).

---

How does dolasetron’s chemistry drive excipient selection for ANZEMET?

Featured snippet answer: Excipient selection is driven by dolasetron’s need for controlled pH, solubilization support, and chemical stability across manufacturing, storage, and administration. Injectable products typically require a carefully engineered balance between buffer strength, tonicity, solubilizers, and preservatives/antioxidants.

Oral tablet excipient strategy: dissolution and handling

Typical oral excipient objectives for dolasetron tablets:

• Disintegration acceleration: superdisintegrants (e.g., croscarmellose sodium, crospovidone) to reduce variability in gastric emptying impacts.
• Wetting and dissolution support: surfactants or hydrophilic polymers that reduce interfacial tension.
• Granule flow and compression robustness: binders that prevent dose drift during tableting.
• Moisture control: low-hygroscopic excipients, optimized particle size, and desiccant/film coating strategies where needed.

Commercial implication: Small formulation shifts (same API, different excipient system) rarely win alone in US exclusivity terms, but they can win in bioequivalence efficiency, stability shelf-life, and manufacturing robustness. Those translate into lower unit cost and lower lot failure rates.

Injectable excipient strategy: stability and infusion compatibility

Injectable excipient objectives:

• Buffer system and pH control: target pH windows that suppress degradation pathways.
• Solubilizer selection: surfactants or cosolvents to maintain dolasetron in solution and prevent micro-precipitation under thermal cycling.
• Tonicity agents: maintain isotonicity for reduced infusion irritation and consistent osmolality.
• Antioxidant/chelation (where relevant): protect against oxidative degradation and metal-catalyzed pathways.
• Preservative strategy: dependent on multidose vs single-dose presentation and sterility assurance concept.

Commercial implication: Injectable differentiation can be operational. If a new product reduces pharmacy prep steps, reduces medication errors, or improves stability after dilution, it can earn formulary adoption even where clinical advantage is incremental.

---

What excipient strategies create differentiation without changing the API dose?

Featured snippet answer: The most defensible differentiation usually comes from formulation-specific targets (dissolution profile, chemical stability, and compatibility) rather than excipient swaps alone.

High-leverage formulation levers

• Surfactant system optimization (type and level) to manage micellar solubilization and reduce viscosity/dilution artifacts.
• Polymer selection for oral wetting and dissolution to reduce Cmax variability.
• Particle engineering and blend uniformity controls to support robust bioequivalence.
• Microenvironment control in injectables via buffer strength and ionic composition.
• Fill-finish and container-closure compatibility design to reduce leachables or adsorption losses.

What tends to be commercially “sticky”

• Shelf-life extension enabled by improved stability excipient choices.
• Reduced lot failures due to better moisture tolerance and controlled crystallization behavior.
• Better performance under cold-chain and room-temperature excursion if tolerated by stability data.

---

When does ANZEMET lose exclusivity and what generic entry risks exist?

Featured snippet answer: A precise exclusivity and patent expiration timeline cannot be produced here because the necessary current FDA listing identifiers (NDA number, Orange Book patent list, and any pediatric exclusivity or granted exclusivity dates) are not provided.

Generic entry risk framework for dolasetron

Even without a precise timeline, generic entry risk for a parenteral CINV product generally depends on:

• Whether the injectable is still marketed and how it is referenced by ANDAs (and whether an AB-rated generic exists).
• Bioequivalence pathway feasibility for the oral tablet (standard BE vs special requirements if exposure is sensitive).
• Whether formulation/process patents create Paragraph IV leverage (especially for injectables where stability claims are common).
• Whether the market has shifted to competing CINV agents (risk of demand capture is separate from patent status).

Commercial implication: For an excipient-focused entrant, the “entry risk” often is not clinical. It is a combination of (1) whether you can launch with an abbreviated dossier without triggering formulation/process patents and (2) whether you can match or beat stability and usability metrics that the reference listed product sets.

---

What is the Orange Book status of ANZEMET, and which patents are listed?

Featured snippet answer: Orange Book patent listings cannot be enumerated here without the active NDA and the current Orange Book dataset. A complete “listed patents” table would require those record keys.

How excipient entrants should read Orange Book tables

When listings are available, excipient strategy should map to:

• Drug substance (API) patents: usually hard to design around; excipient-led entry is not a substitute.
• Drug product (formulation) patents: the primary target for excipient optimization and design-around.
• Method-of-use patents: important for labeling or new indications, less so for excipient-only differentiation.
• Exclusivity and exclusivity extensions: pediatric, marketing exclusivity, and other statutory periods that can block ANDA approval even where patent design-around exists.

---

Which CINV competitors set the excipient and usability bar for dolasetron products?

Featured snippet answer: In CINV, formulary expectations increasingly prioritize dosing simplicity, low administration burden, and compatibility with common infusion protocols. Excipient-driven improvements that reduce pharmacy friction can matter as much as minor stability or taste improvements.

Competitive bench: what substitutes influence demand

• 5-HT3 antagonists: include products with different stability and formulation characteristics (oral vs IV ready-to-use formats).
• NK1 antagonists and corticosteroids: shift the regimen baseline, affecting where dolasetron fits in clinical practice.
• Fixed or multi-agent regimen workflows: usability becomes a decisive factor.

Commercial implication: A differentiated excipient strategy is most valuable when it supports a differentiated product presentation (e.g., ready-to-use injectable, fewer steps, better post-dilution stability).

---

How does ANZEMET injectable stability after dilution impact pharmacy adoption?

Featured snippet answer: For IV CINV agents, the key is whether the product maintains chemical integrity and physical stability after dilution in real-world infusion media. Excipient choices that sustain stability under typical dilution volumes and light/temperature conditions can drive adoption.

What to target in a stability program

• Chemical stability: dolasetron and degradant levels over shelf life and post-dilution windows.
• Physical stability: precipitation, clarity, particle formation, and adsorption risk.
• pH drift: caused by infusion fluid composition.
• Compatibility with common co-administered agents: where admixture is expected by label or local practice.

Commercial implication: If a new formulation expands the validated post-dilution window, it reduces waste and improves throughput in infusion centers.

---

What commercial opportunities exist for excipient-led line extensions of dolasetron?

Featured snippet answer: The highest probability opportunities are practical differentiators: improved stability, reduced prep steps, and robust dosing performance. These can be used for commercial pull through distribution, formulary, and procurement because they reduce operational risk.

Opportunity map

• Injectable format modernization
  • ready-to-use presentation (where feasible)
  • single-dose, reduced variability manufacturing strategy
  • expanded validated post-dilution stability window
• Oral bioavailability performance and robustness
  • improved dissolution profile consistency across conditions
  • enhanced moisture stability enabling longer shelf life and fewer returns
• Manufacturing cost and supply resilience
  • excipient systems that lower sensitivity to humidity and scale-up changes
  • reduce lot-to-lot variability that drives batch rejection
• Regulatory positioning
  • stability and compatibility data supporting labeling that aligns with clinical workflow

---

How strong is the patent estate for excipient design-arounds in dolasetron products?

Featured snippet answer: The patent estate’s practical strength is driven by whether formulation claims are narrow (exact compositions) or broad (ranges plus functional features). Injectables often have narrower composition claims but strong stability/compatibility claims that can constrain formulation changes.

Design-around tactics that track formulation claim structures

• If claims specify exact excipient identities: switch excipient grade/source or change excipient class while matching performance targets.
• If claims specify ranges: remain outside the claimed ranges and support bioequivalence and stability through data.
• If claims specify pH and buffer selection: change the buffer system to a different acid/base pair, keeping final pH in unclaimed windows.
• If claims specify process endpoints tied to excipient behavior: re-engineer process controls to a different profile.

Commercial implication: The “best” design-around is the one that preserves manufacturability and stability enough to pass regulatory chemistry, manufacturing, and controls thresholds without ballooning cost.

---

What patent litigation affects ANZEMET or dolasetron generics?

Featured snippet answer: Patent litigation cannot be mapped here without current docket identifiers or a verified litigation dataset for dolasetron/ANZEMET-related filings.

How excipient entrants should think about litigation

Litigation risk tends to concentrate on:

• formulation and process patents for injectables (stability/compatibility claims)
• Paragraph IV challenges alleging non-infringement or invalidity of formulation patents
• settlement agreements that can delay generic launches or require specific design-around formulations

---

What are the key excipient targets for a dolasetron oral tablet generic or new entrant?

Featured snippet answer: For an oral dolasetron product, the key excipient targets are those that control wetting, disintegration speed, moisture sensitivity, and dissolution profile consistency.

Oral excipient targets

• disintegrant with consistent swelling kinetics
• binder/dispersant system supporting uniform mixing
• lubrication system that maintains low-dose content uniformity
• controlled moisture uptake via film coating and/or low-hygroscopic filler

CMC constraints

• scale-up uniformity
• dissolution test method sensitivity
• bridging across strength if multipotency product line exists

Commercial implication: Oral product differentiation often wins through stability logistics and lower manufacturing rejection rates, not through major clinical benefit.

---

What are the key excipient targets for a dolasetron injectable new formulation?

Featured snippet answer: For injectable dolasetron, excipient selection focuses on buffer system, solubilizer, tonicity, and stability preservatives/antioxidants so the product stays clear and chemically stable during storage and after dilution.

Injectable excipient targets

• buffer with robust pH control and minimal catalytic degradation risk
• solubilizer/cosolvent system that avoids phase separation under temperature excursions
• tonicity agents aligned with infusion compatibility standards
• antioxidant/chelator approach matched to degradation pathway

Regulatory and usability targets

• validated post-dilution time under typical infusion protocols
• container-closure compatibility that avoids adsorption or leachables
• microbiological and preservative efficacy strategy for multidose vs single-dose

---

Key Takeaways

• Excipient strategy for ANZEMET (dolasetron) is most commercially valuable when it improves stability, solubility, and usability rather than when it attempts to differentiate with excipient swaps alone.
• The patent leverage for excipient-led entry typically sits in formulation and process claims that bind exact excipient systems, ranges, and manufacturing endpoints.
• The most actionable commercial opportunities are in injectable presentation and stability after dilution plus oral performance robustness and shelf-life extension.
• A full Orange Book and litigation-informed timeline requires the current NDA and FDA listing identifiers; without those, patent-expiration and generic-launch scenario tables would be incomplete.

---

FAQs

1) Can excipients alone support a differentiated dolasetron injectable without changing clinical dosing?
Yes, if the formulation targets chemical stability, clarity, and post-dilution compatibility in validated assays and supports any required labeling changes.

2) Do excipient-based line extensions create regulatory pathways faster than new indications?
Typically line extensions that modify dosage form or presentation can be faster than new indication strategies, because they rely more on CMC and bridging data than on new efficacy endpoints.

3) What excipient properties most affect oral dissolution variability for dolasetron tablets?
Wetting and disintegration kinetics, moisture uptake behavior, and particle size distribution stability during manufacturing and storage.

4) Which formulation tests best predict injectable performance in infusion centers?
Post-dilution chemical stability, physical clarity/precipitation, pH drift in infusion fluids, and container-closure compatibility metrics.

5) What design-around strategy is most practical when a formulation patent is composition- and pH-range specific?
Change excipient identities and/or buffer systems to move outside claimed ranges and demonstrate stability and bioequivalence through dossier-grade data.

---

References

1. U.S. Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Current listing accessed via FDA databases).
2. FDA. Drug Approval Reports and FDA labels for ANZEMET (dolasetron).
3. FDA. Chemistry, Manufacturing, and Controls (CMC) guidance and stability guidance documents.